NCT03160339 is a Phase 1 clinical trial of PXVX0047 Vaccine in Adenoviral Infection, sponsored by Emergent BioSolutions.

Who is sponsoring NCT03160339?

NCT03160339 is sponsored by Emergent BioSolutions.

What drugs are being tested in NCT03160339?

Interventions in NCT03160339: PXVX0047 Vaccine, Teva Ad4/Ad7 Vaccine.

What condition does NCT03160339 study?

NCT03160339 studies Adenoviral Infection.

Is NCT03160339 still recruiting?

NCT03160339 is currently terminated. Last updated 18 March 2024.

Last reviewed 2024-03-18 · How we verify

NCT03160339

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047

Terminated Phase 1 Last updated 18 March 2024

What this trial tests

Phase 1 trial testing PXVX0047 Vaccine in Adenoviral Infection in 25 participants. Terminated before completion.

Timeline

1 May 2017

Primary endpoint
27 November 2017

27 November 2017

Quick facts

Lead sponsor	Emergent BioSolutions
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	prevention
Enrollment	25
Start date	1 May 2017
Primary completion	27 November 2017
Estimated completion	27 November 2017
Sites	2 locations across United States

Drugs / interventions tested

PXVX0047 Vaccine — full drug profile →
Teva Ad4/Ad7 Vaccine — full drug profile →

Conditions studied

Adenoviral Infection — all drugs for Adenoviral Infection →

Sponsor

Emergent BioSolutions — full company profile →

Who can join

Adults 18 to 35, any sex, with Adenoviral Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

PXVX0047 (Adenovirus Type 4 and Type 7 Vaccine \[A549 Cells\], Live, Oral) is an investigational vaccine in development for the indication of active immunization against adenovirus infection. The primary goals of this Phase 1 study are to evaluate safety, pharmacodynamics (viral shedding), and immunogenicity of PXVX0047.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Noninvasive vaccination against infectious diseases.
Zheng Z, Diaz-Arévalo D, Guan H, Zeng M. · · 2018 · cited 46× · PMID 29624470 · DOI 10.1080/21645515.2018.1461296
Recent advances of engineered oncolytic viruses-based combination therapy for liver cancer.
Zhang J, Xiao Y, Zhang J, Yang Y, et al · · 2024 · cited 8× · PMID 38167076 · DOI 10.1186/s12967-023-04817-w
Differential Genome Replication of a Unique Single-Amino-Acid Mutation in the Adenovirus-4 Component of the Live Oral Adenovirus Type 4 and Type 7 Vaccine.
Collins ND, Beaty S, Wallace E, Li Y, et al · · 2023 · cited 1× · PMID 37514960 · DOI 10.3390/vaccines11071144
A Phase 1 Two-Arm, Randomized, Double-Blind, Active-Controlled Study of Live, Oral Plasmid-Derived Adenovirus Type 4 and Type 7 Vaccines in Seronegative Adults.
Beaty S, Collins N, Karasavvas N, Kuschner R, et al · · 2023 · cited 1× · PMID 37376480 · DOI 10.3390/vaccines11061091

Verify or expand the search:

Other Emergent BioSolutions trials

Trials by the same sponsor.

NCT05935917 — Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults · Phase 1 · completed
NCT05377255 — Pharmacokinetics (PK) and Safety of Multiple Doses of Intranasal Naloxone in Healthy Adults · Phase 1 · completed
NCT05194358 — Study of SIAN Nasal Spray in Healthy Adults · Phase 1 · completed
NCT05142306 — A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes to SARS-CoV-2 Uninfect · Phase 1 · completed
NCT05155319 — Universal Influenza A Vaccine in Healthy Adults · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03160339 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Emergent BioSolutions
Last refreshed: 18 March 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03160339.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing